Menu

NIH Won’t Use Industry Money for Opioid Research Initiative

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

Apr 19, 2018
Shawna Williams

ISTOCK, MITCHELL WESSELLSThe National Institutes of Health (NIH) will exclusively use taxpayer money for a research initiative on the treatment of pain and substance use disorder, STAT News reports. The announced funding is a shift from what had been touted as a potential public-private partnership, with the federal government and drug companies each contributing approximately $200 million to the initiative.

The change comes after an NIH working group recommended last month that only federal funds be used for planned research aimed at alleviating the opioid crisis. The intent is “[t]o mitigate the risk of real or perceived conflict of interest,” the working group noted. The shift away from using private money for the initiative also comes amid controversy over an NIH agency’s courting of industry funders for a proposed study on the health effects of drinking alcohol.

“There’s so much controversy swirling around pharmaceuticals on the opioid issue,” Rep. Tom Cole (R-Okla.), who chairs the House appropriations subcommittee on health, tells STAT, adding that he agrees with NIH’s decision. An NIH spokesperson tells the outlet that the planned research can proceed with only federal funds thanks to budget increases in last month’s omnibus spending bill.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.